The organization stated that it hopes to conduct scientific reviews of clinical trials in the United States, Chile and Peru.
According to CNN, the World Health Organization (WHO) told CNN in a statement on Tuesday that concerns about AstraZeneca’s Covid-19 vaccine efficacy data appear to have nothing to do with safety.
AstraZeneca announced on Monday that US trial data on the Covid-19 vaccine showed 79% efficacy against symptomatic diseases and 100% efficacy against serious diseases and hospitalizations. This is a press release, not official data used by the US Food and Drug Administration to determine whether to grant emergency use authorization for the vaccine.
The National Institute of Allergy and Infectious Diseases (NIAID) in a statement released on Tuesday highlighted the concerns raised by the trial safety and data monitoring committee that AstraZeneca used outdated information from the trial.
The WHO said: “As far as we know, the concerns about NIAID seem to be related to efficacy data, not safety.” “WHO has not seen the data from the US AZ clinical trial, nor has it seen the issue of NIAID. Specific details.”
The WHO said that SKBio’s AstraZeneca Vaccine Advisory Group and Serum Institute of India are providing its emergency use list and recommendations.
The WHO added: “We look forward to scientific reviews of clinical trials in the United States, Chile and Peru.”
.